Everolimus-eluting stent implantation for unprotected left main coronary artery stenosis. The PRECOMBAT-2 (Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease) study.

[1]  C. Terkelsen,et al.  Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention: The Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV) , 2012, Circulation.

[2]  U. Khot,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.

[3]  G. Levine,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.

[4]  G. Stone,et al.  Percutaneous coronary intervention versus coronary artery bypass graft surgery in left main coronary artery disease: a meta-analysis of randomized clinical data. , 2011, Journal of the American College of Cardiology.

[5]  I. Seong,et al.  Randomized Comparison of Everolimus-Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery Disease in Patients With Diabetes Mellitus (ESSENCE-DIABETES): Results From the ESSENCE-DIABETES Trial , 2011, Circulation.

[6]  M. Jeong,et al.  Randomized trial of stents versus bypass surgery for left main coronary artery disease. , 2011, The New England journal of medicine.

[7]  Seung‐Jung Park,et al.  Incidence, predictors, treatment, and long-term prognosis of patients with restenosis after drug-eluting stent implantation for unprotected left main coronary artery disease. , 2011, Journal of the American College of Cardiology.

[8]  G. Schuler,et al.  Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. , 2011, Journal of the American College of Cardiology.

[9]  M. Mack,et al.  Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery Bypass Graft Treatment in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial , 2010, Circulation.

[10]  O. Alfieri,et al.  5-year outcomes following percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass graft for unprotected left main coronary artery lesions the Milan experience. , 2010, JACC. Cardiovascular interventions.

[11]  P. Serruys,et al.  Long-term clinical results following stenting of the left main stem: insights from RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries. , 2010, JACC. Cardiovascular interventions.

[12]  Young-Hak Kim,et al.  Drug-eluting versus bare-metal stents in unprotected left main coronary artery stenosis a meta-analysis. , 2010, JACC. Cardiovascular interventions.

[13]  Gregg W Stone,et al.  Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. , 2010, The New England journal of medicine.

[14]  P. Smits,et al.  Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial , 2010, The Lancet.

[15]  Seung‐Jung Park,et al.  Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgi , 2009, Journal of the American College of Cardiology.

[16]  R. Weiss,et al.  A meta-analysis of 3,773 patients treated with percutaneous coronary intervention or surgery for unprotected left main coronary artery stenosis. , 2009, JACC. Cardiovascular interventions.

[17]  A. Kastrati,et al.  Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. , 2009, Journal of the American College of Cardiology.

[18]  Young-Hak Kim,et al.  Stents versus coronary-artery bypass grafting for left main coronary artery disease. , 2008, The New England journal of medicine.

[19]  Patrick W Serruys,et al.  A novel dedicated quantitative coronary analysis methodology for bifurcation lesions. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[20]  D. Dudek,et al.  Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. , 2008, Journal of the American College of Cardiology.

[21]  P. Teirstein,et al.  A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease. , 2008, American heart journal.

[22]  P. Serruys,et al.  Short- and Long-Term Clinical Outcome After Drug-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease: Insights From the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital Registries (RESEARCH and T-SEARCH) , 2005, Circulation.

[23]  G. Stone,et al.  Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.

[24]  N. Lange,et al.  Approximate case influence for the proportional hazards regression model with censored data. , 1984, Biometrics.

[25]  Volkmar Falk,et al.  Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .